KR20190029642A - 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물 - Google Patents

중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물 Download PDF

Info

Publication number
KR20190029642A
KR20190029642A KR1020197003873A KR20197003873A KR20190029642A KR 20190029642 A KR20190029642 A KR 20190029642A KR 1020197003873 A KR1020197003873 A KR 1020197003873A KR 20197003873 A KR20197003873 A KR 20197003873A KR 20190029642 A KR20190029642 A KR 20190029642A
Authority
KR
South Korea
Prior art keywords
cochleate
antifungal
cryptococcus
days
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197003873A
Other languages
English (en)
Korean (ko)
Inventor
라파엘 제이. 만니노
루잉 루
더그 에프. 클링
Original Assignee
마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 filed Critical 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Priority to KR1020227041763A priority Critical patent/KR20230003167A/ko
Publication of KR20190029642A publication Critical patent/KR20190029642A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197003873A 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물 Ceased KR20190029642A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227041763A KR20230003167A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662361351P 2016-07-12 2016-07-12
US62/361,351 2016-07-12
US201762513800P 2017-06-01 2017-06-01
US62/513,800 2017-06-01
PCT/US2017/041750 WO2018013711A1 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041763A Division KR20230003167A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물

Publications (1)

Publication Number Publication Date
KR20190029642A true KR20190029642A (ko) 2019-03-20

Family

ID=60952715

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227041763A Ceased KR20230003167A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물
KR1020197003873A Ceased KR20190029642A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스(cryptococcus) 감염의 치료를 위한 코클리에이트화된(encochleated) 항진균 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020227041763A Ceased KR20230003167A (ko) 2016-07-12 2017-07-12 중추 신경계 전달 및 크립토코커스 감염의 치료를 위한 코클리에이트화된 항진균 화합물

Country Status (8)

Country Link
US (3) US11123295B2 (enExample)
EP (1) EP3484447A4 (enExample)
JP (1) JP6991592B2 (enExample)
KR (2) KR20230003167A (enExample)
CN (2) CN114053417A (enExample)
AU (1) AU2017297402B2 (enExample)
CA (1) CA3027668A1 (enExample)
WO (1) WO2018013711A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361155B (es) 2012-07-30 2018-11-28 Matinas Biopharma Nanotechnologies Inc Cocleatos hechos con fosfatidilserina de soja.
JP2022544077A (ja) * 2019-08-13 2022-10-17 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド クリプトコッカス感染症を治療する方法
CN118370831A (zh) * 2023-01-20 2024-07-23 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711057A (pt) * 1996-08-09 1999-08-17 Buckman Labor Inc M-todo para aumentar a efic cia de um composto antifÚngio usado para tratar uma infec-Æo fÚngica m-todo para tratar uma infec-Æo fÚngica composi-Æo farmaceutica e m-todo para controlar o crescimento de um organismo fungico em um substrato a ser inserido no corpo
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
WO2001052817A2 (en) 2000-01-24 2001-07-26 Biodelivery Sciences, Inc. Cochleate formulations and their use for delivering biologically relevant molecules
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (en) * 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US20050013854A1 (en) 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
CN105168250B (zh) * 2004-10-25 2019-02-05 塞勒兰特治疗公司 增殖骨髓细胞群体的方法及其应用
NZ561675A (en) * 2005-04-07 2010-07-30 Toyama Chemical Co Ltd Pharmaceutical composition and method using antifungal agent in combination
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DE102008054431B3 (de) * 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
WO2010091090A1 (en) * 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
JP6347743B2 (ja) * 2011-05-05 2018-06-27 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド コクリエート組成物およびその製造および使用方法
MX361155B (es) 2012-07-30 2018-11-28 Matinas Biopharma Nanotechnologies Inc Cocleatos hechos con fosfatidilserina de soja.

Also Published As

Publication number Publication date
US20210393526A1 (en) 2021-12-23
AU2017297402A1 (en) 2019-01-03
AU2017297402B2 (en) 2023-02-09
EP3484447A4 (en) 2020-07-22
CN114053417A (zh) 2022-02-18
CN109689028A (zh) 2019-04-26
KR20230003167A (ko) 2023-01-05
US20200121601A1 (en) 2020-04-23
US11123295B2 (en) 2021-09-21
JP2019520407A (ja) 2019-07-18
JP6991592B2 (ja) 2022-01-12
EP3484447A1 (en) 2019-05-22
CA3027668A1 (en) 2018-01-18
WO2018013711A1 (en) 2018-01-18
US20240423916A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
US20240423916A1 (en) Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections
JP5855829B2 (ja) リポソーム化バンコマイシン製剤
JP5920875B2 (ja) 真菌感染症を治療するための新規な製剤
EP3787601B1 (en) Liposomal nano formulation of combinational antibiotics and the uses thereof
US20230181759A1 (en) Compositions for treatment of viral respiratory infections and methods of use thereof
US9820940B2 (en) Liposomal formulations of polymyxin and uses thereof
JPH07501825A (ja) 高められた抗真菌活性を有するアンフォテリシンｂ組成物
US20220313717A1 (en) Methods of treating cryptococcus infections
EP4572770A1 (en) Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis
CN107920994A (zh) 用于治疗目的的板层小体的组合物和方法
US20250221930A1 (en) A composition comprising lipid nanoparticles and an antifungal polyene
US10092515B2 (en) Liposomal formulations of polymyxin B and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220315

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220315

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221128